Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A case of adalimumab-induced pneumonitis in a 45-year-old man with Crohn's disease.

Literature DB >> 21969926

A case of adalimumab-induced pneumonitis in a 45-year-old man with Crohn's disease.

James D Reid¹, Brian Bressler, John English.

Abstract

Adalimumab is a human monoclonal antibody against tumour necrosis factor-alpha that has been associated with acute lung toxicity, mainly in patients with rheumatoid arthritis. Descriptions of similar patterns of lung injury in patients treated with adalimumab for inflammatory bowel disease are emerging in the literature. A case involving a 45-year-old man with Crohn's disease who developed a nonbronchiolitis inflammatory nodular pattern of lung injury after starting adalimumab is reported.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2011 PMID： 21969926 PMCID： PMC3267602 DOI： 10.1155/2011/713821

Source DB: PubMed Journal: Can Respir J ISSN： 1198-2241 Impact factor: 2.409

8 in total

Review 1. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients.

Authors: S Imokawa; T V Colby; K O Leslie; R A Helmers
Journal: Eur Respir J Date: 2000-02 Impact factor: 16.671

2. Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.

Authors: Samuel A Yousem; Sanja Dacic
Journal: Mod Pathol Date: 2005-05 Impact factor: 7.842

3. Interstitial pneumonitis after infliximab therapy for Crohn's disease.

Authors: Mark Weatherhead; Steven Masson; Stephen J Bourke; Melanie C Gunn; Graham P Burns
Journal: Inflamm Bowel Dis Date: 2006-05 Impact factor: 5.325

Review 4. Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy.

Authors: Gökhan M Mutlu; Ece A Mutlu; Amy Bellmeyer; Israel Rubinstein
Journal: Am J Med Date: 2006-08 Impact factor: 4.965

Review 5. Pulmonary complications of tumor necrosis factor-targeted therapy.

Authors: Krishna Thavarajah; Peggy Wu; Elisa J Rhew; Anjana K Yeldandi; David W Kamp
Journal: Respir Med Date: 2009-02-07 Impact factor: 3.415

Review 6. Noninfectious lung pathology in patients with Crohn's disease.

Authors: Mary B Casey; Henry D Tazelaar; Jeffrey L Myers; Gary W Hunninghake; Sanjay Kakar; Sanjay X Kalra; Rendell Ashton; Thomas V Colby
Journal: Am J Surg Pathol Date: 2003-02 Impact factor: 6.394

7. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan.

Authors: Takao Koike; Masayoshi Harigai; Shigeko Inokuma; Kazuhiko Inoue; Naoki Ishiguro; Junnosuke Ryu; Tsutomu Takeuchi; Yoshiya Tanaka; Hisashi Yamanaka; Koichi Fujii; Bruce Freundlich; Michio Suzukawa
Journal: J Rheumatol Date: 2009-03-30 Impact factor: 4.666

8. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

Authors: Manuel Ramos-Casals; Pilar Brito-Zerón; Sandra Muñoz; Natalia Soria; Diana Galiana; Laura Bertolaccini; Maria-Jose Cuadrado; Munther A Khamashta
Journal: Medicine (Baltimore) Date: 2007-07 Impact factor: 1.889

8 in total

7 in total

1. A Patient with KL-6 Elevation with Anti-TNFα Who Could Receive Long-Term Use without Interstitial Pneumonia after Class Switch of Anti-TNFα.

Authors: Takuya Masuda; Atsushi Yoshida; Fumiaki Ueno; Shintaro Hara; Haruaki Nabeta; Shotaro Umezawa; Mayuki Shirai; Yoshihide Morikawa; Toshio Morizane; Yutaka Endo; Toshifumi Hibi
Journal: Inflamm Intest Dis Date: 2019-03-25

A case of adalimumab-induced pneumonitis in a 45-year-old man with Crohn's disease.

Review 1. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients.

2. Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.

3. Interstitial pneumonitis after infliximab therapy for Crohn's disease.

Review 4. Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy.

Review 5. Pulmonary complications of tumor necrosis factor-targeted therapy.

Review 6. Noninfectious lung pathology in patients with Crohn's disease.

7. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan.

8. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

1. A Patient with KL-6 Elevation with Anti-TNFα Who Could Receive Long-Term Use without Interstitial Pneumonia after Class Switch of Anti-TNFα.

Review 2. Pulmonary manifestations of inflammatory bowel disease.

Review 3. Pulmonary manifestations of Crohn's disease.

4. Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease.

5. Organizing Pneumonia in a Patient with Quiescent Crohn's Disease.

6. Adalimumab induced interstitial lung disease.

7. Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis.